Difference between revisions of "Regimen classes"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
''The purpose of this page is to define regimen classes that will be used in the HemOnc ontology; it is not for other purposes at this time.'' | ''The purpose of this page is to define regimen classes that will be used in the HemOnc ontology; it is not for other purposes at this time.'' | ||
| + | =Generic classes= | ||
| + | ==Chemoradiotherapy== | ||
| + | ==Single-agent regimen== | ||
| + | ===Single-agent cytotoxic chemotherapy=== | ||
| + | ===Single-agent hormonotherapy=== | ||
| + | ===Single-agent immunotherapy=== | ||
| + | ===Single-agent targeted therapy=== | ||
| − | =Alkylator-based regimen= | + | =More specific classes= |
| − | =Anthracycline-based regimen= | + | ==Alkylator-based regimen== |
| + | ==Anthracycline-based regimen== | ||
| − | =Anti-CD20-based regimen= | + | ==Anti-CD20-based regimen== |
| − | ==Rituximab-containing regimen== | + | ===Rituximab-containing regimen=== |
| − | =Anti-HER2-based regimen= | + | ==Anti-HER2-based regimen== |
| − | ==Trastuzumab-based regimen== | + | ===Trastuzumab-based regimen=== |
| − | =Anti-VEGF biologic therapy= | + | ==Anti-VEGF biologic therapy== |
| − | ==Bevacizumab-containing regimen== | + | ===Bevacizumab-containing regimen=== |
| − | =Dacarbazine-based regimen= | + | ==Dacarbazine-based regimen== |
| − | =Endocrine-based regimen= | + | ==Endocrine-based regimen== |
| − | ==Androgen receptor-directed therapy== | + | ===Androgen receptor-directed therapy=== |
| − | ==Antiestrogen therapy== | + | ===Antiestrogen therapy=== |
| − | =Fludarabine-based regimen= | + | ==Fludarabine-based regimen== |
| − | =Fluoropyrimidine-based regimen= | + | ==Fluoropyrimidine-based regimen== |
| − | ==5-FU-based regimen== | + | ===5-FU-based regimen=== |
| − | =Irinotecan-based regimen= | + | ==Irinotecan-based regimen== |
| − | =Pemetrexed-containing regimen= | + | ==Pemetrexed-containing regimen== |
| − | =Platinum-based regimen= | + | ==Platinum-based regimen== |
| − | ==Cisplatin-based regimen== | + | ===Cisplatin-based regimen=== |
| − | ==Oxaliplatin-based regimen== | + | ===Oxaliplatin-based regimen=== |
| − | ==Platinum-based chemoradiation== | + | ===Platinum-based chemoradiation=== |
| − | ==Platinum doublet== | + | ===Platinum doublet=== |
| − | = | + | ==Taxane-based regimen== |
| − | = | + | ===Docetaxel-containing regimen=== |
| − | == | + | ==Temozolomide-based regimen== |
| − | |||
| − | == | ||
| − | = | + | ==Tyrosine kinase inhibitor therapy== |
| − | + | ===BRAF TKI therapy=== | |
| − | + | ===EGFR TKI therapy=== | |
| − | + | ===VEGFR inhibitor therapy=== | |
| − | =Tyrosine kinase inhibitor therapy= | ||
| − | ==BRAF TKI therapy== | ||
| − | ==EGFR TKI therapy== | ||
| − | ==VEGFR inhibitor therapy== | ||
[[Category:Ontology pages]] | [[Category:Ontology pages]] | ||
Revision as of 20:24, 8 September 2022
The purpose of this page is to define regimen classes that will be used in the HemOnc ontology; it is not for other purposes at this time.